Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
Delayed Nasdaq  -  04:00 2022-09-29 pm EDT
118.07 USD   -3.34%
05:37pAround 3.2 million Americans administered updated COVID boosters last week -CDC
RE
11:40aChina Walvax's mRNA COVID vaccine obtains first approval overseas
RE
08:10aModerna, Inc. : Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

UK'S MHRA: UPDATED VERSION OF COVID-19 VACCINE MADE BY MODERNA T…

08/15/2022 | 06:30am EDT

UK'S MHRA: UPDATED VERSION OF COVID-19 VACCINE MADE BY MODERNA THAT TARGETS 2 CORONAVIRUS VARIANTS APPROVED FOR ADULT BOOSTER DOSES BY MHRA


© Reuters 2022
All news about MODERNA, INC.
05:37pAround 3.2 million Americans administered updated COVID boosters last week -CDC
RE
11:40aChina Walvax's mRNA COVID vaccine obtains first approval overseas
RE
08:10aModerna, Inc. : Change in Directors or Principal Officers, Regulation FD Disclosure, Finan..
AQ
06:31aModerna Adds New Role Ahead of Product Launches
DJ
09/28Indonesia approves first home-grown COVID vaccine for emergency use - media
RE
09/28ETF Preview: ETFs, Futures Mixed Pre-Bell After Trade, Mortgage Applications..
MT
09/28Moderna Says European Regulator Approves Omicron-Targeting Bivalent COVID-19 Booster
MT
09/28Indonesia approves first home-grown COVID vaccine for emergency use - media
RE
09/28Moderna's Application for Omicron-specific COVID-19 Booster Accepted for EU Review
MT
09/28European Medicines Agency Accepts Moderna's Conditional Marketing Authorization Filing ..
CI
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2022 21 836 M - -
Net income 2022 10 884 M - -
Net cash 2022 16 503 M - -
P/E ratio 2022 4,67x
Yield 2022 -
Capitalization 47 785 M 47 785 M -
EV / Sales 2022 1,43x
EV / Sales 2023 2,73x
Nbr of Employees 2 700
Free-Float 90,5%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 122,15 $
Average target price 218,07 $
Spread / Average Target 78,5%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
James M. Mock Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-51.91%47 785
LONZA GROUP AG-37.97%35 765
IQVIA HOLDINGS INC.-34.19%34 633
SEAGEN INC.-10.92%25 400
ALNYLAM PHARMACEUTICALS, INC.19.48%25 297
CELLTRION, INC.-13.64%16 012